18-Dec-2025
Bank of America Securities Keeps Their Buy Rating on Quest Diagnostics (DGX)
TipRanks (Mon, 15-Dec 7:25 AM ET)
Barclays Sticks to Its Hold Rating for Quest Diagnostics (DGX)
TipRanks (Mon, 15-Dec 4:27 AM ET)
Business Wire (Mon, 1-Dec 8:30 AM ET)
Engine Capital Issues Open Letter to the Trustees Controlling UniFirst Corporation
Business Wire (Tue, 25-Nov 9:15 AM ET)
Quest Diagnostics Declares Quarterly Cash Dividend
PRNewswire (Tue, 11-Nov 4:30 PM ET)
Quest Diagnostics to Speak at Citi's 2025 Global Healthcare Conference
PRNewswire (Mon, 3-Nov 4:10 PM ET)
New Study Demonstrates Accuracy of Two Quest AD-Detect Tests for Alzheimer's Disease Diagnosis
PRNewswire (Mon, 27-Oct 7:45 AM ET)
Quest Diagnostics Lifts 2025 Outlook on Double-Digit Revenue and EPS Growth
Market Chameleon (Tue, 21-Oct 4:51 AM ET)
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
PRNewswire (Tue, 21-Oct 6:45 AM ET)
WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health
Business Wire (Tue, 30-Sep 9:00 AM ET)
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Quest Diagnostics trades on the NYSE stock market under the symbol DGX.
As of December 18, 2025, DGX stock price declined to $176.15 with 916,224 million shares trading.
DGX has a beta of 0.16, meaning it tends to be less sensitive to market movements. DGX has a correlation of 0.03 to the broad based SPY ETF.
DGX has a market cap of $19.60 billion. This is considered a Large Cap stock.
Last quarter Quest Diagnostics reported $3 billion in Revenue and $2.60 earnings per share. This beat revenue expectation by $87 million and exceeded earnings estimates by $.09.
In the last 3 years, DGX traded as high as $197.55 and as low as $119.59.
The top ETF exchange traded funds that DGX belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
DGX has outperformed the market in the last year with a return of +15.3%, while the SPY ETF gained +13.1%. However, in the most recent history, DGX shares have underperformed the stock market with its stock returning -2.9% in the last 3 month period and -3.5% for the last 2 week period, while SPY has returned +2.9% and -1.1%, respectively.
DGX support price is $176.82 and resistance is $181.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DGX shares will trade within this expected range on the day.